Jose de Jesus Lopez Jimenez

Dr. Jose de Jesus Lopez Jimenez

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Genetics and Molecular Research
Verified
Journal Article
Closed access
JJJose de Jesus Lopez Jimenez
Jose de Jesus Lopez Jimenez
ÁPÁ. Porras-Dorantes
Á. Porras-Dorantes
CJC.I. Juárez-Vázquez
C.I. Juárez-Vázquez
JGJ.E. García-Ortiz
J.E. García-Ortiz
CFC.A. Fuentes-Chávez
C.A. Fuentes-Chávez
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz
Idiopathic recurrent pregnancy loss (IRPL) is defined by three or more consecutive miscarriages occurring before the twentieth week of gestation as a result of unidentified etiological factors. The results of previous studies have indicated that prothrombotic factors play a pathogenic role in early and late pregnancy. This study aimed to identify inherited prothrombotic and hypofibrinolytic risk factors in Mexican-Mestizo patients with IRPL. Fifty-six women with IRPL and 50 control women with at least two full-term pregnancies and no history of RPL were included in this case-control study. Four prothrombotic (F5 G1691A, F2 G20210A, MTHFR C677T-A1298C) and one hypofibrinolytic (PAI1 4G/5G) restricted fragment length polymorphisms were subjected to molecular analysis. In the case of hypofibrinolytic ACE Ins/Del (I/D), identification was performed by direct PCR. The independent risk correlated with the presence of polymorphisms in IRPL patients was estimated using odds ratio (OR) with a 95% confidence interval (CI). MTHFR 677TT was the most frequent prothrombotic factor in the IRPL group (23%), followed by the compound-heterozygous C677T-A1298C (16%) and heterozygous F2 20210GA (3.6%). The heterozygous ACE I/D (62%) was the main hypofibrinolytic risk factor of IRPL, followed by the homozygote PAI1 4G/4G (18%). The ACE I/D polymorphism was the only significantly different factor among the cases and controls. The dominant genetic model D/D+I/D vs I/I showed an OR (95%CI) of 2.89 (1.22-6.89) and P = 0.019 in Mexican-Mestizo women. The results of this study support an association between the ACE I/D polymorphism and IRPL risk in a Mexican population.

30 September 2019 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
JJJose de Jesus Lopez Jimenez
Jose de Jesus Lopez Jimenez
RORicardo Ortega‐Cervantes
Ricardo Ortega‐Cervantes
HLHilda Luna-Záizar
Hilda Luna-Záizar
ARAna lilia Fletes Rayas
Ana lilia Fletes Rayas
CBClaudia‐Patricia Beltrán‐Miranda
Claudia‐Patricia Beltrán‐Miranda
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz
Background: The pathophysiology of hemophilic arthropathy is complex and not completely understood. In this study, we aimed to identify biomarkers that can affect the hemophilic arthropathy severity.Methods: Fifty patients were analyzed for biomarker frequencies; in 37 patients, articular symptoms were evaluated based on the physical joint examination score, and in 18, it was based on magnetic resonance imaging. Eight polymorphisms, namely FV 1691G>A, FII 20210G>A, MTHFR 677C>T and 1298A>C, TNFα‐308G>A and ‐238G>A, ACAN VNTR, and IL1RN*2‐VNTR were identified.Results: Patients with the MTHFR 677TT genotype showed a higher number of affected joints (1.83 ± 0.9 vs. 0.55 ± 0.7 for CC; p = .023), whereas those with the MTHFR 1298AC genotype exhibited higher effusion according to two radiologists (0.90 ± 0.31/1.20 ± 0.63 vs. 0.38 ± 0.52/0.50 ± 0.53 for AA genotype; p = .043/0.036, respectively). In addition, patients with the TNFα‐308GA genotype had more subchondral cysts (0.75 ± 0.95 vs. 0.07 ± 0.26 for GG genotype; p = .041).Conclusions: The distribution of risk genotypes for MTHFR and TNFα‐308GA suggests their association with clinical parameters of hemophilic arthropathy. Cohort studies are essential to verify these associations.

26 October 2009 in Haemophilia
Verified
Journal Article
Closed access
PDF file
JJJose de Jesus Lopez Jimenez
Jose de Jesus Lopez Jimenez
CBC. P. Beltrán‐Miranda
C. P. Beltrán‐Miranda
JMJ. M. Mantilla‐Capacho
J. M. Mantilla‐Capacho
MEM. A. Esparza‐Flores
M. A. Esparza‐Flores
LGL. C. López González
L. C. López González
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz

Verified
Journal Article
Open access
PDF file
JNJacqueline Alejandra Noboa-Velástegui
Jacqueline Alejandra Noboa-Velástegui
RVRodolfo Iván Valdez vega
Rodolfo Iván Valdez vega
JAJorge Castro Albarrán
Jorge Castro Albarrán
PMPerla Monserrat Madrigal-Ruiz
Perla Monserrat Madrigal-Ruiz
ARAna lilia Fletes Rayas
Ana lilia Fletes Rayas
RNRosa Elena Navarro
Rosa Elena Navarro
Extracellular vesicles (EVs), particularly exosomes, are key mediators of intercellular communication, transporting biomolecules such as nucleic acids, lipids, and proteins that influence immune and metabolic pathways. In adipose tissue (AT), adipocyte-derived EVs (AdEVs) play a crucial role in maintaining metabolic homeostasis and have been implicated in obesity-related dysfunction. Among their bioactive cargo, microRNAs regulate post-transcriptional gene expression and participate in immunometabolic regulation. This study aimed to determine whether miR-34a expression in serum and circulating EVs varies according to body fat percentage, to explore its potential utility as a non-invasive biomarker of AT dysfunction. A total of 142 adults (mean age 36 ± 11 years) were classified by body fat percentage (≥25% in men, ≥35% in women). Exosomes were isolated (Invitrogen®) and characterized by cryo-TEM, and miR-34a expression was quantified by qRT-PCR. miR-34a expression correlated negatively with Total Cholesterol, Triglycerides, LDLc/HDLc, TG/HDLc, BMI, C3, CRP, fasting insulin, HOMA-IR, HOMA-B, Body adiposity, Chemerin, CCL2, AdipoQT, and AdipoQ-H, but positively with HDLc and QUICKI. Notably, LDLc, sdLDLc, sdLDLc/LDLc, TC/HDLc, and fasting glucose showed opposite correlation patterns between serum and exosomes. Overall, serum miR-34a levels were higher than in exosomes, suggesting its potential as a biomarker of metabolic dysfunction and insulin resistance.

6 January 2011
Verified
Journal Article
Closed access
RRRoberto Carlos Rosales-Gómez
Roberto Carlos Rosales-Gómez
JJJose de Jesus Lopez Jimenez
Jose de Jesus Lopez Jimenez
NNNelly Yazmine Núñez-Reveles
Nelly Yazmine Núñez-Reveles
AGAna Elizabeth González-Santiago
Ana Elizabeth González-Santiago
SRSergio Alberto Ramírez-García
Sergio Alberto Ramírez-García

10 October 2011 in Haemophilia
Verified
Journal Article
Closed access
PDF file
CBC. P. Beltrán-Miranda
C. P. Beltrán-Miranda
HLHilda Luna-Záizar
Hilda Luna-Záizar
JJJose de Jesus Lopez Jimenez
Jose de Jesus Lopez Jimenez
JMJ. M. Mantilla-Capacho
J. M. Mantilla-Capacho
MLM. Laffan
M. Laffan
AJAna Rebeca Jaloma-Cruz
Ana Rebeca Jaloma-Cruz